New York — QuantHealth, a leader in AI-powered clinical trial simulation, has unveiled a groundbreaking new foundation model designed to transform how pharmaceutical companies approach clinical development. The company’s Large Real-World Drug Model (LRDM v1.0) is the first AI foundation model specifically built for clinical applications, capable of simulating outcomes using data from over 100 million patients and billions of therapeutic datapoints.
Traditionally, AI in the pharmaceutical industry has focused on drug discovery. QuantHealth’s LRDM v1.0 shifts the focus to clinical trials—the most expensive and failure-prone phase of drug development. With over 90 percent of candidates failing during clinical testing and more than half of total R&D budgets spent at this stage, the model aims to drastically improve decision-making, trial design, and overall success rates.
“This is a major milestone in applying AI at the clinical stage,” said Orr Inbar, CEO and co-founder of QuantHealth. “Healthcare produces 30 percent of the world’s data—about 138 billion gigabytes a day—and making sense of that in life sciences is a monumental challenge. We’ve spent four years and over $10 million on R&D to build this model, and we’re now seeing that investment pay off.”
QuantHealth’s model, built on transformer-based architectures, integrates systems biology, clinical data modeling, and large-scale biomedical knowledge graphs. The result is a system that not only simulates trial outcomes with high precision but also adapts to rare diseases and small patient subgroups through advanced transfer learning techniques.
“LRDM v1.0 is trained on 100 million patients and 30 billion drug-patient pairs, with 138 million parameters,” said Eran Barash, Head of Machine Learning and AI at QuantHealth. “It’s about 100 times larger than our previous model and leverages 500 times more data, allowing it to detect nuanced clinical patterns and reason about drug mechanisms at an unprecedented depth.”
Currently, QuantHealth supports clinical trials for eight of the world’s top 20 pharmaceutical companies, contributing to dozens of studies annually across oncology, cardiovascular, and autoimmune diseases. Its simulations help sponsors design more precise and efficient trials, accelerating patient recruitment and reducing both time and cost.
The LRDM model will be made available on the AWS Marketplace, expanding access to QuantHealth’s technology through self-service simulation tools and API integrations. AWS is partnering with the company to bring the new model to a broader range of life sciences clients.
“QuantHealth’s model addresses both scientific and economic challenges in clinical trials,” said Dan Sheeran, General Manager of Healthcare and Life Sciences at AWS. “We’re excited to deepen our collaboration with QuantHealth to help pharma companies improve trial fidelity and raise their chances of success.”
With the launch of LRDM v1.0, QuantHealth is positioning itself at the forefront of a new frontier in AI-driven clinical development, enabling pharmaceutical companies to make better-informed decisions, reduce trial failures, and bring innovative therapies to market faster.
